Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

JPM Parting Shots: Milestones Ahead For Prothena, Sage, Aimmune, UniQure

This article was originally published in Scrip

Executive Summary

It takes weeks to recover from the biopharma industry's yearly pilgrimage to San Francisco, so as Scrip continues to sort through notes taken and business cards collected during the 34th Annual J.P. Morgan Healthcare Conference from Jan. 11 to 14, we've put together some pipeline updates from interviews that didn't make it into our initial reporting from the meeting.

You may also be interested in...



Aimmune Gets $145m From Nestlé To Advance Food Allergy Immunotherapies

With the sizeable investment, Nestlé Health Sciences also gets a three-month right of first negotiation for licensing or partnering to develop any Aimmune candidates, including Phase III AR101 for peanut allergy.

Prothena CEO Dale Schenck Dies From Pancreatic Cancer

Prothena CEO Dale Schenk, the scientist behind innovative medicines that included bapineuzumab and Tysabri, died from pancreatic cancer on Sept. 30 – less than two years after he revealed his diagnosis.

Sage Drug Could Help Take Stigma Out Of Postpartum Depression

SAGE Therapeutics Inc. could offer the one in eight new mothers suffering from postpartum depression (PPD) freedom from the overwhelming condition with the first-ever drug to specifically treat PPD if the rapid and durable response to SAGE-547 in a small Phase II clinical trial holds up in future studies.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC064510

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel